We evaluated the activity of the nAlb conjugated STING agonist (nAlb-diABZI) as well as the parent DBCO-PEG11-diABZI compound and a previously optimized diABZI23 (compound 3; referred to henceforth as diABZI) in two human reporter cell lines for type-I interferon (IFN-I) production: monocytes (THP1-Dual) and lung carcinoma cells (A549-Dual) (Fig. 1h,i). This evidence concerns the gene STING1 and lung carcinoma.